Characterization of hepatic lipid profiles in a mouse model with nonalcoholic steatohepatitis and subsequent fibrosis

被引:68
|
作者
Saito, Kosuke [1 ]
Uebanso, Takashi [2 ]
Maekawa, Keiko [1 ]
Ishikawa, Masaki [1 ]
Taguchi, Ryo [1 ]
Nammo, Takao [2 ]
Nishimaki-Mogami, Tomoko [3 ]
Udagawa, Haruhide [2 ]
Fujii, Masato [4 ]
Shibazaki, Yuichiro [4 ]
Yoneyama, Hiroyuki [4 ]
Yasuda, Kazuki [2 ]
Saito, Yoshiro [1 ]
机构
[1] Natl Inst Hlth Sci, Div Med Safety Sci, Setagaya Ku, 1-18-1 Kamiyoga, Tokyo 1588501, Japan
[2] Natl Ctr Global Hlth & Med, Diabet Res Ctr, Res Inst, Dept Metab Disorder,Shinjuku Ku, Tokyo 1628655, Japan
[3] Natl Inst Hlth Sci, Div Biochem, Setagaya Ku, Tokyo 1588501, Japan
[4] Stel Inst & Co Inc, Tokyo 1060044, Japan
来源
SCIENTIFIC REPORTS | 2015年 / 5卷
关键词
FATTY LIVER-DISEASE; ACCUMULATION; INFLAMMATION; ASSOCIATION; POPULATION; PREVALENCE; EXPRESSION; CIRRHOSIS; PLASMA; INJURY;
D O I
10.1038/srep12466
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Nonalcoholic steatohepatitis (NASH) is a major health problem since it often leads to hepatocellular carcinoma. However, the underlying mechanisms of NASH development and subsequent fibrosis have yet to be clarified. We compared comprehensive lipidomic profiles between mice with high fat diet (HFD)-induced steatosis and STAM mice with NASH and subsequent fibrosis. The STAM mouse is a model that demonstrates NASH progression resembling the disease in humans: STAM mice manifest NASH at 8 weeks, which progresses to fibrosis at 12 weeks, and finally develop hepatocellular carcinoma. Overall, 250 lipid molecules were detected in the liver using liquid chromatography-mass spectrometry. We found that STAM mice with NASH presented a significantly higher abundance of sphingolipids and lower levels of triacylglycerols than the HFD-fed control mice. The abundance of certain fatty acids in phospholipid side chains was also significantly different between STAM and control mice, although global levels of phosphatidylcholines and phosphatidylethanolamines were comparable. Finally, increase in levels of acylcarnitines and some diacylglycerols was observed in STAM mice toward the fibrosis stage, but not in age-matched control mice. Our study provides insights into the lipid status of the steatotic, NASH, and fibrotic liver that would help elucidate the molecular pathophysiology of NASH progression.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Emerging drugs for the treatment of hepatic fibrosis on nonalcoholic steatohepatitis
    Iwaki, Michihiro
    Yoneda, Masato
    Wada, Naohiro
    Otani, Tomohiro
    Kobayashi, Takashi
    Nogami, Asako
    Saito, Satoru
    Nakajima, Atsushi
    EXPERT OPINION ON EMERGING DRUGS, 2024, 29 (02) : 127 - 137
  • [22] Nonalcoholic Steatohepatitis (NASH) and Hepatic Fibrosis: Emerging Therapies
    Wattacheril, Julia
    Issa, Danny
    Sanyal, Arun
    ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 58, 2018, 58 : 649 - 662
  • [23] Hepatic gene expression in patients with nonalcoholic steatohepatitis in relation to hepatic fibrosis
    Taniai, Makiko
    Hashimoto, Etsuko
    Tobari, Maki
    Takakura, Mihoko
    Yatsuji, Satoru
    Tokushige, Katsutoshi
    Shiratori, Keiko
    GASTROENTEROLOGY, 2006, 130 (04) : A767 - A767
  • [24] Targeting the Mitochondrial Pyruvate Carrier Attenuates Fibrosis in a Mouse Model of Nonalcoholic Steatohepatitis
    McCommis, Kyle S.
    Hodges, Wesley T.
    Brunt, Elizabeth M.
    Nalbantoglu, Ilke
    McDonald, William G.
    Holley, Christopher
    Fujiwara, Hideji
    Schaffer, Jean E.
    Colca, Jerry R.
    Finck, Brian N.
    HEPATOLOGY, 2017, 65 (05) : 1543 - 1556
  • [25] Effects of renalase deficiency on liver fibrosis markers in a nonalcoholic steatohepatitis mouse model
    Tokinoya, Katsuyuki
    Sekine, Nanami
    Aoki, Kai
    Ono, Seiko
    Kuji, Tomoaki
    Sugasawa, Takehito
    Yoshida, Yasuko
    Takekoshi, Kazuhiro
    MOLECULAR MEDICINE REPORTS, 2021, 23 (03)
  • [26] Inhibition of plasminogen suppresses fibrosis and macrophage foaming in a nonalcoholic steatohepatitis mouse model
    Tomonari, Yuki
    Iwaki, Takayuki
    Arakawa, Tomohiro
    Umemura, Kazuo
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2022, 36 (05) : 827 - 836
  • [27] Novel Mouse Model of Nonalcoholic Steatohepatitis
    Shin, Ji-Yeon
    Hernandez-Ono, Antonio
    Fedotova, Tatyana
    Lee, Michael J.
    Ostlund, Cecilia
    Dauer, William T.
    Ginsberg, Henry N.
    Worman, Howard J.
    HEPATOLOGY, 2017, 66 : 1079A - 1079A
  • [28] Sugar kelp (Saccharina latissima) inhibits hepatic inflammation and fibrosis in a mouse model of diet-induced nonalcoholic steatohepatitis
    Kim, Mi-Bo
    Lee, Yoojin
    Bae, Minkyung
    Kang, Hyunju
    Hu, Siqi
    Pham, Tho X.
    Lee, Ji-Young
    Park, Young-Ki
    JOURNAL OF NUTRITIONAL BIOCHEMISTRY, 2021, 97
  • [29] Inhibition of NADPH Oxidase in Phagocytes Improves Hepatic Steatosis, Inflammation and Fibrosis in a Mouse Model of Severe Nonalcoholic Steatohepatitis (NASH)
    Golden-Mason, Lucy M.
    McMahan, Rachel
    Campbell, Eric L.
    Cheng, Linling
    Orlicky, David J.
    Rosen, Hugo R.
    HEPATOLOGY, 2017, 66 : 1089A - 1090A
  • [30] EFFECT OF ARB AND RIFAXIMIN COMBINATION THERAPY ON HEPATIC FIBROSIS IN NONALCOHOLIC STEATOHEPATITIS MODEL RATS
    Fujinaga, Yukihisa
    Kawaratani, Hideto
    Namisaki, Tadashi
    Moriya, Kei
    Kaji, Kosuke
    Takaya, Hiroaki
    Sawada, Yasuhiko
    Akahane, Takemi
    Sato, Shinya
    Shimozato, Naotaka
    Saikawa, Soichiro
    Nakanishi, Keisuke
    Kubo, Takuya
    Furukawa, Masanori
    Yoshiji, Hitoshi
    HEPATOLOGY, 2019, 70 : 1294A - 1294A